Clinical trial NCT02099825: Medication Enhanced Rapid Therapy
Official title: Medication Enhanced Rapid Therapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Anxiety Disorders
Keywords: adult male
anxiety
public speaking
healthy controls
exposure therapy
social anxiety
mifepristone
d-cycloserine
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2014-03-31
Enrollment: 15
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to determine whether taking a one-time dose of a combination of putatively learning-enhancing medications can improve treatment response to a brief learning-based psychotherapy for public speaking anxiety. The two medications are (1) d-cycloserine (DCS), a medication that is an agonist (facilitator) of the NMDA glutamatergic receptor and has been shown in previous studies to facilitate some kinds of learning and memory; and (2) mifepristone, a medication that blocks cortisol, and in preclinical (animal) studies has been shown to reverse certain kinds of stress-related learning impairment or negative learning.

Specifically, the investigators goal is to determine if DCS and mifepristone taken together augment the learning that occurs during a brief psychotherapy session---a public speaking exposure exercise. Evidence for this learning effect would be a finding that participants have reduced anxiety at subsequent public speaking exposures.

Detailed description: The study has a total of 4 visits, and the medications are given as a one-time dose at only one visit (the second visit).

1. During the first visit, a trained clinical interviewer will provide informed consent and conduct a structured clinical interview. Participants will be included if they are adult males diagnosed with social anxiety disorder and express a fear of public speaking, as well as approximately 10 healthy control participants. Eligible participants will be asked to complete self-report ratings of social anxiety and psychological symptoms and a standard interview about anxiety symptoms. The experimenter will conduct neuropsychological tests used to measure the participant's cognitive functioning.
2. At the second visit the participant will be administered a one-time only dosage of both medications. The participant will be asked to prepare a speech within a short period of time, this is an example of exposure therapy. In exposure therapy, people are exposed to a situation they fear, such as public speaking, in a safe and controlled environment. Often when people do exposure therapy, they find that the situations they have been afraid of are not actually as scary as they seem. The exposure exercise in this study will consist of giving a speech while being video-recorded. Before the exposure exercise, participants will be provided with 250mg DCS and up to 1200mg of mifepristone. Participants will rate their anxiety level and negative and positive affect before and after the speech, as well as during the speech. The experimenter will again conduct neuropsychological tests used to measure the participant's cognitive functioning.
3. (3) \& (4) During the next two visits, participants will complete a second and third public speaking exposure exercise identical to the first, with the exception that they will NOT receive medication. Participants will complete a similar battery of symptom measures and anxiety ratings. The investigators will look at a change in anxiety ratings and symptomatology between exposure session 1, exposure session 2, and exposure session 3.

Eligibility criteria: For Potential Participants suffering from Social Anxiety Disorder or Social Phobia:

Inclusion Criteria:

* Male
* at least 18 years old
* current diagnosis of Social Anxiety Disorder or Social Phobia
* fear of public speaking
* medically stable and in good health
* if currently taking antidepressant treatment, must be on a stable dose for at least 8 weeks
* Liebowitz Social Anxiety Scale score of at least 30

Exclusion Criteria:

* Female
* inability to provide informed consent
* current or lifetime diagnosis of bipolar disorder, psychotic disorder or eating disorder
* current substance abuse or dependence within the last 6 months
* any cognitive, sensory, or communication problem that would prevent completion of the study
* severe mental health symptoms that require immediate treatment (i.e. active suicidality)
* current use of medication for diagnosis of one or more of the following: seizure disorder, kidney disease, liver disease
* current cancer (or history of metastatic cancer)
* current or recent use (within past 3 months) of systemic corticosteroids
* diabetic individuals
* untreated or unstable endocrinologic disease (i.e. hyperthyroidism)
* lifetime history of Cushing's disease or Addison's disease

For Control Group:

Inclusion Criteria:

* Male
* at least 18 years old
* no current diagnosis of Social Anxiety Disorder or Social Phobia
* reports no fear of public speaking
* Liebowitz Social Anxiety Scale score below or equal to 29

Exclusion Criteria:

* Female
* inability to provide informed consent
* current or lifetime diagnosis of bipolar disorder, psychotic disorder or eating disorder
* current substance abuse or dependence within the last 6 months
* any cognitive, sensory, or communication problem that would prevent completion of the study
* severe mental health symptoms that require immediate treatment (i.e. active suicidality)
* current use of medication for diagnosis of one or more of the following: seizure disorder, kidney disease, liver disease
* current cancer (or history of metastatic cancer)
* current or recent use (within past 3 months) of systemic corticosteroids
* diabetic individuals
* untreated or unstable endocrinologic disease (i.e. hyperthyroidism)
* lifetime history of Cushing's disease or Addison's disease

Primary outcomes:
measure: Will measure medication tolerability and safety per participant report (i.e. few or no side effects severe enough to stop treatment)
timeFrame: End of Session 2--(7-10 days after Session 1)
Secondary outcomes:
measure: Improvements in Anxiety as measured by several Self Report Assessments
timeFrame: Session 2- 1st exposure therapy session, occurs 7-10 days after Session 1
measure: Level of Anxiety as measured by several Self Report Assessments
timeFrame: Session 1- initial self reports collected;
measure: Improvements in Anxiety as measured by several Self Report Assessments
timeFrame: Session 3- 2nd exposure therapy session- occurs 7- 10 days after Session 2
measure: Improvements in Anxiety as measured by several Self Report Assessments
timeFrame: Session 4- 3rd exposure therapy- occurs 3 months later
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Eric J Lenze, MD
role: PRINCIPAL_INVESTIGATOR
References: